Latest Options Exercise News

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.

Sprintex Limited reported a 162% surge in revenue to A$2.7 million for the half-year ending December 2025, driven by a landmark €15.6 million European contract. Despite this, the company posted a net loss of A$1.7 million, an improvement from the prior year, while raising $3.6 million to support global expansion.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Catalina Resources has divested its Nelson Bay River iron ore project and secured a capital injection from Newcam Metals at a significant premium, bolstering its financial position for future exploration.

Morella Corporation has raised A$2.1 million through a placement to fund drilling at its Mt Edon Rubidium–Lithium Project, marking a key step toward defining a maiden mineral resource estimate.

Westar Resources is set to raise $1.49 million through a two-tranche share placement aimed at funding exploration and new project due diligence. The placement features discounted share prices and awaits shareholder approval for the larger second tranche.

Celsius Resources has raised A$9.3 million through a well-supported institutional placement, strengthening its balance sheet to advance the financing and early development of its flagship MCB copper-gold project in the Philippines.

PVW Resources has completed its acquisition of Southern Prospecting, gaining full ownership of the Cobb Creek Project in Nevada with a historical gold estimate of 173,000 ounces. The move marks a significant shift towards North American precious metals exploration.

Kuniko Limited has raised A$3.75 million in a strongly supported placement to fast-track drilling and resource expansion at its Commonwealth Gold–Silver Project in NSW’s Lachlan Fold Belt. Phase I drilling is underway, with results expected in April 2026.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

3D Energi Limited has offered 41.7 million free attaching options to investors from its October 2025 Placement, aiming to clear trading restrictions despite ongoing ASX suspension and financial challenges.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.